Defiance Hotel, Airline, and Cruise ETF에 대한 매도 수량은 투자자에게 Defiance Hotel, Airline, and Cruise ETF의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Defiance Hotel, Airline, and Cruise ETF (ARCA:CRUZ), 공매도 수량 보고

Consumer Cyclical

Industrials

Real Estate

The Fund will generally use a replication strategy to achieve its investment objective, meaning the Fund will generally invest in all of the component securities of the Index in the same approximate proportions as in the Index. However, the Fund may use a representative sampling strategy, meaning it may invest in a sample of the securities in the Index whose risk, return, and other characteristics closely resemble the risk, return, and other characteristics of the Index as a whole, when the Funds sub-adviser believes it is in the best interests of the Fund (e.g., when replicating the Index involves practical difficulties or substantial costs, an Index constituent becomes temporarily illiquid, unavailable, or less liquid, or as a result of legal restrictions or limitations that apply to the Fund but not to the Index).

Hilton Worldwide Holdings, Inc.

Marriott International, Inc.

Royal Caribbean Cruises Ltd.

Delta Air Lines Inc.

Carnival Corp.

Ryanair Holdings Plc

Intercontinental Hotels Group Plc, Adr

United Airlines Holdings Inc.

Southwest Airlines Co.

Host Hotels & Resorts Inc.

Defiance Hotel Airline and Cruise ETF

Analyst Color

Equities

Large Cap

News

Analyst Ratings

Trading Ideas

CRUZ

PowerShares ETF Leisure & Entertainment Port

로얄 캐리비안 크루즈(NYSE:RCL)의 주가가 화요일에 혼재된 3분기 실적을 발표 후 3% 이상 상승했다. 매출은 전년 대비 17.5% 증가한 48억 9천만 달러로, 컨센서스인 49억 달러를 밑돌았고, 조정된 주당순이익(EPS)은 5.20 달러로 컨센서스인 5.03 달러를 상회했다.

로얄 캐리비안의 3분기 EPS는 예상을 상회했지만, 골드만삭스는 4분기 비용에 대해 경고

Defiance Hotel, Airline, and Cruise ETF

CRUZ BATTERY METALS CORP by Cruz Battery Metals Corp.

Cruz Battery Metals Corp

<p>Citigroup  analyst Alicia Yap   maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Buy and raises the price target from $108 to $115.</p>


Price Target

NTES

Citigroup Maintains Buy on NetEase, Raises Price Target to $115

<p>Citigroup  analyst Alicia Yap   maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and lowers the price target from $52 to $51.</p>


Citigroup Maintains Buy on JD.com, Lowers Price Target to $51

<p>Alliance Global Partners  analyst Gaurav Mehta   downgrades Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) from Buy to Neutral and announces $2 price target.</p>


Downgrades

SACH

Alliance Global Partners Downgrades Sachem Cap to Neutral, Announces $2 Price Target

<p><a href="https://www.politico.com/news/2024/11/15/trump-transition-steven-cheung-communications-director-00189857">https://www.politico.com/news/2024/11/15/trump-transition-steven-cheung-communications-director-00189857</a></p>
<p>Steven Cheung, who served as Donald Trump's principal spokesperson on his 2024 campaign and also served on his 2020 and 2016 campaigns, is joining the White House as communications director, according to a person with direct knowledge of the matter.</p>
<p>Cheung has been a near constant presence at Trump's side and a key member of his tight-knit presidential campaign, run by Susie Wiles and Chris LaCivita.</p>


Macro Economic Events

Politics

Economics

General

'Trump To Tap Campaign Spokesperson Steven Cheung As Communications Director' - Politico

<p>Alliance Global Partners  analyst Jeff Grampp   maintains Drilling Tools Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTI#NASDAQ">DTI</a>) with a Buy and lowers the price target from $7.5 to $5.5.</p>


Alliance Global Partners Maintains Buy on Drilling Tools Intl, Lowers Price Target to $5.5

Econ #s

U.S. Baker Hughes Oil Rig Count -1 At 478; U.S. Baker Hughes NatGas Rig Count -1 At 101; U.S. Baker Hughes Total Rig Count 584 Vs 585 Prior

<p>Wedbush  analyst Andreas Argyrides   reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and maintains $181 price target.</p>


Reiteration

ASND

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $181 Price Target

<p>Across the recent three months, 14 analysts have shared their insights on Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.36, a high estimate of $27.00, and a low estimate of $19.00. Experiencing a 10.31% decline, the current average is now lower than the previous average price target of $24.93. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693679_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Couchbase is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Austin Dietz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Couchbase. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Couchbase compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Couchbase's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Couchbase's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BASE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Couchbase analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Couchbase: A Closer Look</h2>
<p>Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.</p>
<h3>A Deep Dive into Couchbase's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Couchbase displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately <strong>19.59%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Couchbase's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-38.56%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Couchbase's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-15.56%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Couchbase's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-8.32%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Couchbase's debt-to-equity ratio is below the industry average. With a ratio of <b>0.03</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BASE

Navigating 14 Analyst Ratings For Couchbase

<p>In the latest quarter, 11 analysts provided ratings for Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $335.91, with a high estimate of $380.00 and a low estimate of $271.00. Observing a 7.25% increase, the current average has risen from the previous average price target of $313.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693672_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Equifax by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$333.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$304.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$307.00</td>
<td>$277.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Equifax. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Equifax compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Equifax's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Equifax's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EFX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Equifax analyst ratings.</strong></a></p>
<h2>All You Need to Know About Equifax</h2>
<p>Along with Experian and TransUnion, Equifax is one of the leading credit bureaus in the United States. Equifax's credit reports provide credit histories on millions of consumers, and the firm's services are critical to lenders' credit decisions. In addition, over 40% of the firm's revenue comes from workforce solutions, which provides income verification and employer human resources services. Equifax generates just over 20% of its revenue from outside the United States.</p>
<h3>Unraveling the Financial Story of Equifax</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Equifax showcased positive performance, achieving a revenue growth rate of <strong>9.3%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Equifax's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.8%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.94%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Equifax's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.15%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.11</strong>, Equifax adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 11 Analyst Ratings For Equifax

<p>In the latest quarter, 15 analysts provided ratings for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $68.4, with a high estimate of $85.00 and a low estimate of $58.00. Witnessing a positive shift, the current average has risen by 4.16% from the previous average price target of $65.67.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693662_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of CVS Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CVS Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for CVS Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CVS Health's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CVS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on CVS Health analyst ratings.</strong></a></p>
<h2>Get to Know CVS Health Better</h2>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<h3>CVS Health: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>6.31%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> CVS Health's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>0.09%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CVS Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.12%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.03%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.1</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For CVS Health's Future

BRK/B

DOCU

LDOS

REGN

CNBC Halftime Report Final Trades: Berkshire Hathaway Inc. - B Shares, Regeneron Pharmaceuticals, DocuSign, Leidos Holdings

<p>MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for MPLX, revealing an average target of $49.12, a high estimate of $55.00, and a low estimate of $43.00. Marking an increase of 2.63%, the current average surpasses the previous average price target of $47.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693651_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of MPLX's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to MPLX. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MPLX compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of MPLX's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MPLX's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MPLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MPLX analyst ratings.</strong></a></p>
<h2>Discovering MPLX: A Closer Look</h2>
<p>MPLX is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in 2019.</p>
<h3>A Deep Dive into MPLX's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining MPLX's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>2.28%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> MPLX's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>37.14%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> MPLX's ROE excels beyond industry benchmarks, reaching <strong>7.52%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.68%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> MPLX's debt-to-equity ratio is below the industry average at <strong>1.66</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MPLX

8 Analysts Have This To Say About MPLX

<p>Claros Mortgage Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMTG#NYSE">CMTG</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.44, a high estimate of $8.00, and a low estimate of $6.50. Highlighting a 7.92% decrease, the current average has fallen from the previous average price target of $8.08. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693642_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Claros Mortgage Trust among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$8.50</td>
</tr>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Underperform</td>
<td>$7.25</td>
<td>$6.75</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Underweight</td>
<td>$8.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Claros Mortgage Trust. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Claros Mortgage Trust compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Claros Mortgage Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Claros Mortgage Trust's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CMTG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Claros Mortgage Trust analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into Claros Mortgage Trust's Background</h2>
<p>Claros Mortgage Trust Inc is a real estate investment trust. The company is focused mainly on originating senior and subordinate loans on transitional commercial real estate assets located in markets across the U.S.</p>
<h3>Financial Milestones: Claros Mortgage Trust's Journey</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Claros Mortgage Trust faced challenges, resulting in a decline of approximately <strong>-22.84%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Claros Mortgage Trust's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-97.54%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Claros Mortgage Trust's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-2.64%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Claros Mortgage Trust's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.76%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.8</strong>, Claros Mortgage Trust adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CMTG

Critical Insights From Claros Mortgage Trust Analyst Ratings: What You Need To Know

<p>Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $84.25, with a high estimate of $91.00 and a low estimate of $80.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.61%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693635_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Albany Intl among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald Epstein</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Michael Ciarmoli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Ciarmoli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$91.00</td>
<td>$101.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Albany Intl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Albany Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Albany Intl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Albany Intl's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AIN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Albany Intl analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Albany Intl</h2>
<p>Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.</p>
<h3>Understanding the Numbers: Albany Intl's Finances</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Albany Intl's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>6.15%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Albany Intl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>6.04%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Albany Intl's ROE excels beyond industry benchmarks, reaching <strong>1.84%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Albany Intl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.03%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.37</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Albany Intl: Insights From 4 Analyst Reviews

<p>DA Davidson  analyst Clark Wright   maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Buy and maintains $42 price target.</p>


ZETA

DA Davidson Maintains Buy on Zeta Global Holdings, Maintains $42 Price Target

<p><strong>ACI Worldwide's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACIW#NYSE">ACIW</a>) short percent of float has fallen 7.67% since its last report. The company recently reported that it has <strong>2.19 million shares sold short</strong>, which is 3.01% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.56 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>ACI Worldwide Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693621_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for ACI Worldwide has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing ACI Worldwide's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ACI Worldwide's peer group average for short interest as a percentage of float is 8.21%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

ACIW

Peering Into ACI Worldwide's Recent Short Interest

<p><strong>Saia's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NYSE">SAIA</a>) short percent of float has risen 12.98% since its last report. The company recently reported that it has <strong>2.22 million shares sold short</strong>, which is 10.62% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.6 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Saia Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693615_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Saia has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Saia's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Saia's peer group average for short interest as a percentage of float is 4.80%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


SAIA

How Is The Market Feeling About Saia?

<p>Vertically integrated cannabis company<strong> C21 Investments Inc.</strong> (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CXXI#CSE">CXXI</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTCQX">CXXIF</a>) announced its interim unaudited financial statements and management discussion and analysis on Thursday for its second quarter ending Sept. 30, 2024.</p>
<p>"We are pleased with the strong performance and positive customer reception of our new dispensary during its first quarter of operations," said <strong>Sonny Newman,</strong> CEO and president. "These results have exceeded our expectations and we continue to see robust sales growth into the new quarter.&#8221;</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40131597/cannabis-co-c21-investments-reports-stub-period-revenue-of-4-5m-following-3-5m-deep-roots-harves">Cannabis Co. C21 Investments Reports Stub Period Revenue Of $4.5M Following $3.5M Deep Roots Harvest Acquisition</a></strong></p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</em></strong></li>
</ul>
<h3 class="wp-block-heading">Q2 Financial Highlights</h3>
<p>The company said there is no equivalent time period to the second quarter report in the company&#8217;s historical results due to the previously reported change in fiscal year end from Jan. 31 to March 31.</p>
<ul>
<li>Revenue totaled $7.5 million, representing a 14% increase from the first quarter.</li>
<li>Gross margin rose to 43.5%, up from 31% in the prior quarter, fueled by operational efficiencies and higher retail revenues.</li>
<li>The South Reno dispensary ramped up sales by 53% within the quarter, reaching $416,000 in Sept. and continued to perform well post-quarter. The dispensary sales increased by 14% in Oct. reaching $475,000.</li>
<li>Adjusted EBITDA came in positive at $1.3 million, up from $0.3 million in the previous period, reflecting better margins and retail growth.</li>
<li>Free cash flow turned positive, reaching $0.8 million, compared to a negative $0.09 million in the first quarter.</li>
<li>Net loss decreased to $845,132.</li>
<li>Selling, general and administrative expenses increased by 3% increase due to the new dispensary's lease and labor costs.</li>
<li>Total assets grew to $58.6 million, while liabilities increased to $28.3 million. The South Reno dispensary sales increased by 14% in October, reaching $475,000.</li>
</ul>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41338043/the-biggest-little-company-in-cannabis-c21-investments-dominates-reno-nv"><strong>The Biggest Little Company In Cannabis: C21 Investments Dominates Reno, NV</strong></a></li>
</ul>


Cannabis

Earnings

CSE:CXXI

CXXIF

C21 Reports Q2 Revenue Up 14% QoQ,  South Reno Cannabis Dispensary Sees 53% Sales Growth

<p><strong>Morningstar's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NYSE">MORN</a>) short percent of float has fallen 20.0% since its last report. The company recently reported that it has <strong>118 thousand shares sold short</strong>, which is 0.44% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.0 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Morningstar Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693610_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Morningstar has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Morningstar's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Morningstar's peer group average for short interest as a percentage of float is 2.85%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


MORN

Looking Into Morningstar's Recent Short Interest

<p>Wedbush  analyst Seth Basham   reiterates Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Outperform and maintains $55 price target.</p>


Wedbush Reiterates Outperform on Advance Auto Parts, Maintains $55 Price Target

Strong dollar stretches Americans' vacation money but there's a cost to the U.S. economy

Operational Challenges Limit The Altitude For Airline Travel As Demand Climbs

JETS: Despite Booming Demand, Airlines Still Struggle With Profitability

Summer travel: U.S. airport security screenings top 3M in a single day in new record

June U.S. Retail Sales Show Surprising Vigor

Retail Sales Excl. Autos And Gasoline Jump By Most In 18 Months, Push Up Atlanta Fed GDPNow To 2.5%

Travel ETFs: Riding The Wave Of Consumer Demand

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The pullbacks in some of the top <a href="https://investorplace.com/industries/consumer-discretionary/travel/cruise/">cruise stocks</a> are all buying opportunities.</p>



<p>Look at <strong>Royal Caribbean</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/rcl-stock-quote/"><strong>RCL</strong></a></span>), for example.</p>



<p>Even with strong booking demand and earnings growth, the stock dropped from about $173 to a recent low of about $152, where it&rsquo;s now oversold and pivoting higher. Not only did it just catch support at its 50-day moving average, but it&rsquo;s also excessively oversold on RSI and Williams&rsquo; %R. While expecting RCL to resume its uptrend, I&rsquo;d buy the temporary weakness.</p>



<p>From its last traded price of $157, I&rsquo;m looking for an initial retest of $173.&nbsp;</p>



<p>Helping, <a href="https://seekingalpha.com/news/4128143-royal-caribbean-cruises-non-gaap-eps-of-321-beats-by-046-revenue-of-411b-beats-by-60m-reinstates-dividend">RCL just raised its adjusted earnings per share</a> outlook to a new range of $11.35 to $11.45 from an older range of $10.70 to $10.90. The company even reinstated a 40-cent dividend, payable on Oct. 11. That, coupled with explosive demand makes Royal Caribbean a strong buy at current prices.</p>



<p>However, it&rsquo;s not just RCL that could rally to higher highs. Here are three more cruise stocks that could see plenty of smooth sailing ahead, too.</p>



<h2><strong>Carnival (<strong>CCL</strong>)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/ccl1600-300x169.png" alt="Carnival (CCL) logo sign in the night at their headquarters in Miami, Florida, USA. Carnival Cruise Line is an international cruise line."><div>Source: JHVEPhoto / Shutterstock.com</div></div><p>Oversold at $17.12, <strong>Carnival</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/ccl-stock-quote/"><strong>CCL</strong></a></span>) is another one of the top cruise stocks to buy.</p>



<p>For one, the company managed to beat EPS estimates in each of its last seven quarters. Two, in its <a href="https://www.carnivalcorp.com/node/75226/pdf">most recent earnings report,</a> company bookings are at record highs this year and are significantly exceeding 2023 numbers. Three, CCL is already touting record bookings for 2025 as well.</p>



<p>Even better, the company saw customer deposits hit a record high of $8.3 billion in the second quarter, which was $1.1 billion higher than a prior record high.</p>



<p>Helping, over the last few days, <strong>JPMorgan </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/jpm-stock-quote/"><strong>JPM</strong></a></span>) raised its price target on CCL to $25 with a Buy rating. Analysts at Truist also raised their price target to $25 with a hold rating. In total, 14 <a href="https://www.tipranks.com/stocks/ccl/forecast">analysts rate CCL a buy.</a> Two have a Hold rating, and one has a Sell rating, which makes no sense. The average price target on CCL is currently $21.72.&nbsp;</p>



<h2><strong>Norwegian Cruise Line (<strong>NCLH</strong>)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/nclh-1600-300x169.png" alt="Norwegian Cruise Line ship docked in Saint Petersburg. NCLH stock."><div>Source: Nazar Skladanyi / Shutterstock</div></div><p>Oversold at its 100-day moving average, <strong>Norwegian Cruise Line</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/nclh-stock-quote/"><strong>NCLH</strong></a></span>) is also a buy.</p>



<p>Just this morning, the company <a href="https://seekingalpha.com/news/4130981-norwegian-cruise-lines-earns-record-q2-revenue">posted beat</a> top and bottom line estimates. EPS of 40 cents beat by 6 cents. Revenue of $2.4 billion, up 8.6% year-over-year, beat by $20 million. Adjusted EBITDA jumped 14% to $587.7 million.&nbsp;</p>



<p>NCLH also raised its <a href="https://www.nclhltd.com/news-media/press-releases/detail/620/norwegian-cruise-line-holdings-reports-strong-second">full-year adjusted</a> net income guidance by $60 million to about $790 million from $730 million. It also increased its adjusted EPS guidance to $1.53 from $1.42.</p>




<p>Better, <a href="https://seekingalpha.com/news/4130981-norwegian-cruise-lines-earns-record-q2-revenue">according to CEO Harry Sommer,</a> &ldquo;The momentum we are garnering from strong yield growth, disciplined cost&nbsp;management and the initiatives that comprise our Charting the Course strategy further bolsters our confidence in achieving our previously announced 2026 financial and sustainability targets.&rdquo;&nbsp;</p>




<p>I&rsquo;d also use recent weakness as a buying opportunity with NCLH, too. With patience, I&rsquo;d like to see the stock rally back to $21.50 initially.</p>



<h2><strong>Defiance Hotel, Airline and Cruise ETF (<strong>CRUZ</strong>)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/06/cruise-stocks1600-300x169.png" alt="Tourist girl with backpack and hat standing in front of big cruise liner. Cruise stocks"><div>Source: Zigres / Shutterstock.com</div></div><p>Or, if you&rsquo;d rather diversify at a lower cost, there&rsquo;s the exchange-traded fund<strong>&nbsp;Defiance Hotel, Airline, and Cruise</strong> (NYSEARCA:<span><a href="https://investorplace.com/stock-quotes/cruz-stock-quote/"><strong>CRUZ</strong></a></span>). After catching strong support at $21 dating back to February, it&rsquo;s also a buy, as it just starts to pivot higher. Last trading at $21.31, I&rsquo;d like to see it initially retest $22.40.</p>



<p>With an expense ratio of 0.45%, the CRUZ ETF holds 63 top cruise, hotel and <a href="https://investorplace.com/industries/consumer-discretionary/travel/airline/"></a>airline stocks, including <strong>Hilton Worldwide</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/hlt-stock-quote/"><strong>HLT</strong></a></span>), <strong>Marriott</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/mar-stock-quote/"><strong>MAR</strong></a></span>), Royal Caribbean, Carnival, <strong>Delta Air Lines</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/dal-stock-quote/"><strong>DAL</strong></a></span>) and <strong>Southwest Airlines</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/luv-stock-quote/"><strong>LUV</strong></a></span>) &mdash; to name a few of the top holdings.&nbsp;Not only do you get exposure to top cruise stocks but also some of the best hotel and&nbsp;airline stocks &mdash; all for less than $22 a share at the moment.</p>



<p>With the CRUZ ETF, I&rsquo;d use the recent, temporary weakness as a buying opportunity.</p>



<p><em>On the date of publication, Ian Cooper&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned.&nbsp;The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a></em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/07/the-top-3-cruise-stocks-to-buy-now-summer-2024/">The Top 3 Cruise Stocks to Buy Now: Summer 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Comments

Defiance Hotel, Airline, and Cruise ETF

매도 수량

Defiance Hotel, Airline, and Cruise ETF (ARCA:CRUZ), 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌